Kite Pharma, Inc.
Kite Pharma, Inc. (KITE): 8 pipeline candidates · ~65 mo cash runway · 24 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
64.9 months
D/E 0.28 · 0% dilution
Lead: Phase 3
8 candidates
N/A
N/A
A transparent, data-derived signal for Kite Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$147.8M
Quarterly Burn
$34.9M
Runway
64.9 mo
Revenue
$10.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| anti-cd19 car-based product candidate | Phase 1 |
| car-based product candidate targeting egfrviii | Preclinical |
| kite-439 | Phase 3 |
| kite-585 | Phase 3 |
| kite-718 | Phase 3 |
| kite-796 | Phase 3 |
| kte-c19 | Phase 3 |
| tcr-based product candidates targeting ssx2 | Preclinical |
Frequently asked questions
How many drug candidates are in Kite Pharma, Inc.'s pipeline?
Kite Pharma, Inc. (KITE) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kite Pharma, Inc.'s lead drug candidate?
Kite Pharma, Inc.'s most advanced tracked candidate is anti-cd19 car-based product candidate (Phase 1) for B cell lymphomas and leukemias.
What is Kite Pharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kite Pharma, Inc. has approximately 64.9 months of cash runway.
Who is the CEO of Kite Pharma, Inc.?
Arie Belldegrun, M.D. is the chief executive officer of Kite Pharma, Inc. (KITE).
Get the full picture on Kite Pharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.